20 July 2018
Welcome Prof. Dr. Ondrej Slaby to the Editorial Board of Non-Coding RNA
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
We are pleased to announce that Prof. Dr. Ondrej Slaby from the Central European Institute of Technology (CEITEC) and Masaryk Memorial Cancer Institute (Brno, Czech Republic) has joined the Editorial Board of the journal Non-Coding RNA (ISSN 2311-553X). Dr. Slaby is an internationally recognized leader in non-coding RNA research and oncology, and we firmly believe that his expertise will be a worthwhile addition to our esteemed group of experts.
Prof. Dr. Ondrej Slaby graduated and completed his Ph.D. at Masaryk University (Brno, Czech Republic) in medical biochemistry.
Currently, Prof. Dr. Slaby is leading his research group at the Central European Institute of Technology (CEITEC). His research focuses on the study of the diagnostic and therapeutic potential of ncRNAs (e.g., microRNAs and lncRNAs) in oncology. His investigations comprise several cancers, such as colorectal cancer, renal cell carcinoma, and glioblastoma. To date, Prof. Dr. Slaby has discovered several new oncogenic and tumor-suppressive non-coding RNAs in solid cancer (e.g., miR-215 or long non-coding RNA ZFAS1). A combined microRNA/piRNA signature identified by his group is now under development as a new certified diagnostic in colorectal cancer.
Prof. Dr. Slaby believes in a bright future and strong translational potential of non-coding RNAs for the diagnosis and therapy of cancer.